Albumin-bound paclitaxel describes the content of Abraxane (generic name, paclitaxel protein-bound particles), a chemotherapeutic medication in which the chemotherapeutic agent, paclitaxel, is bound to a protein, albumin. Use of Abraxane is FDA-approved for the treatment of metastatic breast cancer that either did not respond to combination chemotherapy or was diagnosed within 6 months of adjuvant chemotherapy.
For each treatment with Abraxane, the drug is given intravenously (through the vein) as an infusion.
Inside cancer cells, paclitaxel works by interfering with the cell cycle and interfering with structures (known as microtubules, which are) involved in cell multiplication. Furthermore, paclitaxel-treated cancer cells undergo apoptosis, a programmed process in which the cancer cell destroys itself.